JP2024544562A - 癌およびウイルス感染に対し機能不全であるヒトｔ細胞およびｂ細胞の回復ためのヒト化モノクローナル抗体 - Google Patents

癌およびウイルス感染に対し機能不全であるヒトｔ細胞およびｂ細胞の回復ためのヒト化モノクローナル抗体 Download PDF

Info

Publication number
JP2024544562A
JP2024544562A JP2024528532A JP2024528532A JP2024544562A JP 2024544562 A JP2024544562 A JP 2024544562A JP 2024528532 A JP2024528532 A JP 2024528532A JP 2024528532 A JP2024528532 A JP 2024528532A JP 2024544562 A JP2024544562 A JP 2024544562A
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
amino acid
δ42pd1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024528532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544562A5 (enExample
Inventor
チェン，ジーウェイ
ジョウ，ドンヤン
リウ、リー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Versitech Ltd
Original Assignee
Versitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versitech Ltd filed Critical Versitech Ltd
Publication of JP2024544562A publication Critical patent/JP2024544562A/ja
Publication of JP2024544562A5 publication Critical patent/JP2024544562A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024528532A 2021-11-15 2022-11-15 癌およびウイルス感染に対し機能不全であるヒトｔ細胞およびｂ細胞の回復ためのヒト化モノクローナル抗体 Pending JP2024544562A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163264061P 2021-11-15 2021-11-15
US63/264,061 2021-11-15
PCT/CN2022/132000 WO2023083377A1 (en) 2021-11-15 2022-11-15 Humanized monoclonal antibody for restoring dysfunctional human t and b cells against cancer and viral infection

Publications (2)

Publication Number Publication Date
JP2024544562A true JP2024544562A (ja) 2024-12-03
JP2024544562A5 JP2024544562A5 (enExample) 2024-12-10

Family

ID=86335085

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024528532A Pending JP2024544562A (ja) 2021-11-15 2022-11-15 癌およびウイルス感染に対し機能不全であるヒトｔ細胞およびｂ細胞の回復ためのヒト化モノクローナル抗体

Country Status (5)

Country Link
US (1) US20250002581A1 (enExample)
EP (1) EP4433508A4 (enExample)
JP (1) JP2024544562A (enExample)
CN (1) CN118382641A (enExample)
WO (1) WO2023083377A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026036133A1 (en) * 2024-08-09 2026-02-12 Scineuro Therapeutics Inc. POTENT, AGGREGATE-SELECTIVE ANTI-Aβ ANTIBODIES AND USES THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140302070A1 (en) * 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105950715B (zh) * 2016-04-27 2019-04-26 深圳市第三人民医院 检测δ42pd1的方法、引物及试剂盒

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140302070A1 (en) * 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHENG L ET AL.: "Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV", MABS, vol. vol.7:3, JPN6025046107, 2015, pages 620 - 629, ISSN: 0005903866 *

Also Published As

Publication number Publication date
EP4433508A1 (en) 2024-09-25
EP4433508A4 (en) 2025-11-19
US20250002581A1 (en) 2025-01-02
CN118382641A (zh) 2024-07-23
WO2023083377A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
JP7143452B2 (ja) ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用
US20220135675A1 (en) Anti-tim-3 antibodies and use thereof
JP2021008487A (ja) 抗ｎｋｇ２ａ抗体を使用した治療計画
KR20250143360A (ko) 종양 항원을 타겟으로 하는 키메릭 항원 수용체
US20240218074A1 (en) Anti-cd73 antibody and use thereof
CN113543804A (zh) 抗lilrb2抗体及其使用方法
KR20200105849A (ko) 항-tigit 항체 및 치료제 및 진단제로서 이의 용도
JP2021525070A (ja) ヒト由来のアレルゲン特異的抗体を単離する方法およびその使用
BR112020003362A2 (pt) antagonistas de tim-3 para o tratamento e diagnóstico de cânceres
US20260042862A1 (en) Composition
CN109310884A (zh) 治疗或预防肝病的方法
US20250017962A1 (en) Igg4 hinge-containing chimeric antigen receptors targeting glypican-3 (gpc3) and use thereof
CN114106182B (zh) 抗tigit的抗体及其用途
JP6900051B2 (ja) Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬
CN102281898B (zh) Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用
JP7455749B2 (ja) 頭頸部癌の処置
US20250002581A1 (en) Humanized monoclonal antibody for restoring dysfunctional human t and b cells against cancer and viral infection
CN108026176A (zh) 用于增强nk细胞杀伤活性的方法和药物组合物
JP2022078202A (ja) Ｐｒｌ３抗体
JP7539897B2 (ja) ヒトｃｄ１３７に結合する抗体の製剤およびその使用
US20250144214A1 (en) Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereof
JP2025511356A (ja) Ｐｄ－ｌ１及びｃｄ４０を標的とする抗原結合タンパク質及びその製造と応用
CN119053340A (zh) 针对pd-l1和cd137的多特异性结合剂与抗pd-1抗体组合用于治疗癌症
CN109661406A (zh) 靶向肿瘤相关巨噬细胞的抗体及其用途
WO2026086834A1 (zh) 抗ox40抗体在治疗皮炎疾病中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260511

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260707